Wednesday, 25 March 2020

Gene Panel Market Segmentation Detailed Study With Forecast Up To 2019

Market Scenario:
Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           
Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.
It is noted that the increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the PACS market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.
Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.
Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
It is estimated that the Picture Archiving and Communications Systems (PACS) market growth is expected to boost at a CAGR 7.0% during the forecast period of 2017–2023.
Key Players
Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others
Segmentation
The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.
On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.
On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.
On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.
On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.
On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.
Regional Analysis
Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.
The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.
Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.
The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Transgenic Animals Market Segmentation Detailed Study With Forecast Up To 2019

Market Scenario:
Transgenic animals or genetically modified (GM) animals have a foreign gene inserted into their DNA structure for various applications such as production of drugs, resistance to disease, and increasing yields. For instance, GM cows, sheep, and goats can produce growth hormone, insulin, and anticoagulants. The global transgenic animals market report by Market Research Future (MRFR) contains a compilation of drivers, threats, and opportunities which can work well for interested investors.
In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
Key players For Transgenic Animals Market
  • Cyagen Biosciences,
  • Charles River,
  • Creative-Biolabs,
  • TRANS GENIC INC.., Ltd.,
  • Sutter Instrument Company,
  • Bio-Rad Laboratories, Inc.,
  • Spinco Biotech Pvt Ltd.,
  • Abbott,
  • Thermo Fisher Scientific Inc.,
  • Sigma-Aldrich Co.,
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others.
On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others.
On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
Browse Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/transgenic-animals-market-5464

Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...TOC Continued!
Posted by at No comments:

Asthma Devices Market 2019 Share, Trend, Segmentation And Forecast To 2023

Asthma Device Market Research Report: By Type (Inhalers, Nebulizers, Dry Powder Inhalers, Metered-Dose Inhalers, Mesh Nebulizers) By Technology (Manually Operated, Digitally Operated) By End Users (Hospital, Retail Pharmacies) – Global Forecast till 2023
Market Synopsis of Global Asthma Devices Market
Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease. Increasing prevalence of asthma is one of the major drivers for the market growth. According to the World Health Organization in 2017, approximately 235 million people suffered from asthma. Moreover, it was estimated that in 2015, the disease killed approximately 383 million patients around the globe. Additionally, rising healthcare expenditures and increasing awareness fuel the market growth. However, long treatment procedures and low per capita income followed by lack of favorable reimbursement policies in the developing countries will restrain the market growth during the forecast period.
The global asthma devices market size is expected to grow at an approximate CAGR of 4.3% during the forecast period. 
Segmentation
The global copd and asthma devices market is segmented on the basis of type, technology, and end users.
On the basis of the type, the market is segmented into inhalers, nebulizers, and others. The inhalers segment is sub-segmented into metered-dose inhalers and dry powder inhalers. The metered-dose inhalers segment, by inhalers, is further categorized into standard pressurized metered-dose inhalers, breath-activated pressurized metered-dose inhalers, metered-dose inhalers with a spacer, and others. The nebulizers segment is sub-segmented into compressor nebulizers, ultrasonic nebulizers, mesh nebulizers, and others.
On the basis of technology, the market is segmented into manually operated inhaler devices, digitally operated inhaler devices, and others.
On the basis of end users, the market is segmented into hospital, clinics, retail pharmacies, and others.
Regional Analysis 
The Americas dominate the global asthma devices market owing to a well-developed healthcare sector and huge patient population for asthma diseases. According to the Centres for Disease Control and Prevention, in 2015, approximately, 7.8% of the total population in the U.S. was identified for the presence of asthma. Moreover, changing lifestyle and increasing healthcare expenditure fuels the market growth. Additionally, the presence of global players like Merck & Co., Inc. and Baxter, and others boost market growth during the forecast period. 
Europe is the second largest asthma devices market owing to a well-developed healthcare infrastructure and huge patient population. Moreover, government support for research & development and rising healthcare expenditures fuel the market growth. According to a study published in the Asthma Research and Practice journal in 2017, the yearly estimated cost for all the asthmatics per patient is about USD 1,900. Additionally, the presence of the developed economies like the U.K, Germany, and France within the region boosts the market growth. 
Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China. According to a study of the Indian Chest Society in 2015, 300 million people suffered from asthma worldwide and about a tenth of its share is in India. Moreover, as per the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020. Moreover, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax along boosts the market growth. 
On the other hand, the Middle East & Africa holds the least share of the global asthma devices market due to the presence of poor economy, especially within the African region. The absence of the developed healthcare sector and stringent government policies restrain the market growth within the African region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures. 
Key players for global asthma devices market
GlaxoSmithKline plc. (Europe), Merck & Co., Inc. (U.S.), 3M (U.S.), Aristopharma Ltd. (Asia Pacific), SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific), AstraZeneca (Europe), Baxter. (U.S.), Boehringer Ingelheim GmbH (Europe), Koninklijke Philips N.V. (Europe), and others.
Detailed Table of Contents:
  1. Report Prologue
  2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
  1. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
  1. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
  1. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces Analysis
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger And Acquisition Landscape
5.7 Upcoming Trends
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Posted by at No comments:

Anaplasmosis Treatment Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Scenario

Anaplasmosis is a bacterial infection that spreads from animals to humans. More rarely, the bacteria that cause anaplasmosis can spread through direct contact with infected animals. The infection can be treated successfully with antibiotics. According to the Centers for Disease Control and Prevention (CDC), the global burden of human anaplasmosis treatment remains high as the organism causes more than 10,000 infections per year worldwide. Usually, anaplasmosis is more common in males than in females and are generally not occurring in infants.
The frequency of reported cases of anaplasmosis is highest among people over 40 years of age. A compromised immune system such as patients undergoing cancer treatments, advanced human immunodeficiency virus infection, prior organ transplants may increase the risk of the severe outcome. Individuals working or spending time in known tick habitats such as the zoo, animal rearing, and farms may be at increased risk for infection.
Although anaplasmosis infections can occur during any time of the year, the majority of cases reported to the CDC have an illness onset during the summer months and peaks in the months of June and July. This period is the season for the proliferation of nymphal black-legged ticks that bite humans and may transmit the pathogen.
The global market for anaplasmosis treatment is expected to grow at a CAGR of approximately 6.3% during the forecast period 2017-2023.
Segmentation
The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.
On the basis of the species, the market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis, the market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application, the market is segmented into humans, pets, livestock, wildlife, and others
On the basis of the treatment, the market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, and others.
Key Players
Some of key the players in the global anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany)  Novopharm (Canada), and others.
Regional Analysis
The global anaplasmosis treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East, and Africa.
The American anaplasmosis treatment is the largest market across the globe owing to the high investment in various private and government-funded research, and increased spending on pharmaceutical industry. This condition is commonly reported from the upper midwestern and northeastern United States. the black-legged tick (Ixodes scapularis) is responsible for transmission of A. phagocytophilum in the upper Midwest and northeastern U.S. These tick species also transmit the agents of Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover, the human co-infections with these organisms have occasionally been reported. Anaplasmosis treatment is now being controlled in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock.
European market is projected to hold the second largest share of the global anaplasmosis treatment market as due to the eradication of these disease from Europe. Although some clinical cases of human granulocytic anaplasmosis have been reported in Europe, mostly from Slovenia, Sweden, and Poland, most cases have occurred in the United States. According to the U.S. National Library of Medicine, the prevalence of Ixodes ricinus ticks in Europe is 3% which is as higher than the United States. The average prevalence rate of A. phagocytophilum infection among humans in Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle Eastern region are expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the healthcare sector.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Bone Biopsy Market, Segments, Growth And Value Chain 2019

Market Scenario
Bone Biopsy market growth is driven by increasing prevalence of chronic diseases such as Chronic Kidney Disease (CKD) and demand new diagnostic services. Additionally, increasing research and development activities, technological advancements to identify the causes and risk factors associated with osteopenia and osteoporosis also fuel the market growth of global market.
The Global Bone Biopsy System Market Size is expected to grow at a CAGR of 5.7% during the forecast period.
According to the World Health Organisation (WHO), cancer was the leading cause of the total number of deaths globally as of 2015 and was responsible for 8.8 million deaths. The most common causal agents identified are cigarettes, cigars, pipes and chewing tobacco. According to the Cancer Research U.K, looking at the lifestyle factors responsible, it has been found that out of 3 diagnosed cases, 1 may be linked to smoking.
Bone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease. Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics. The demand for needle biopsy is found to be increasing from last few years.
Key Players in the Global Bone Biopsy Market     
  • C R Bard (U.S.),
  • Becton,
  • Dickinson and Company (U.S.),
  • Braun Melsungen AG,
  • Hologic, Inc. (U.S.),
  • Cook Medical (U.S.),
  • Devicor Medical Products Inc. (U.S.),
  • Argon Medical Inc. (U.S.)
Segmentation      
The global bone biopsy market is segmented on the basis of type, indication and end user.
On the basis of the component, market is segmented into needle biopsy and open biopsy.
On the basis of the application, the market is segmented into bone cancer, bone infection, chronic kidney disease, osteoporosis, and others
On the basis of the end user, the market is segmented into hospital & clinics, surgical centers, diagnostic centers, and others.
Regional Analysis
America holds the first position in the bone biopsy market owing to the rising prevalence of cancer in the U.S. and increasing demand for new cancer diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare diagnostic industry. The prevalence of osteoporosis is found to be higher in the population over 35 years for age. Changing lifestyle, emphasis on fitness and exercise, and overall development of medical device industry also accelerate the growth of the market.
Europe is the second largest market for bone biopsy. In Europe, there is an increasing demand for advanced bone biopsy devices, and extensive research and development activities by clinical research and academic institutes for cancer diagnosis and treatment. Germany is the largest market followed by France. The market in Germany is driven by increasing demand for specialty care services.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as kidney disease, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand of technologically advanced medical devices in diagnostic centers and availability of highly qualified medical professional dedicated to research in oncology. Additionally, rising healthcare expenditure and extensive growth of medical device industry also influence the use of medical devices for diagnosis of various diseases such as osteoporosis, diabetes, cancer, and others.
The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about cancer treatment. In the Middle East & Africa, United Arab Emirates captures the largest market share for bone biopsy owing to the availability of better healthcare infrastructure and a wide scope for research. In Africa, the market also shows a positive growth owing to development of healthcare system in African countries, and increasing demand for primary care services.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Current And Forthcoming Refsum Disease Market Size In Terms Of Volume And Value 2019

Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2019-2023.
Key Players
  • Fresenius Kabi,
  • Braun Medical Inc.,
  • Medline Industries, Inc.,
  • Illumina, Inc.,
  • Igenomix,
  • Ceuta Healthcare Limited,
  • Cochlear Ltd.,
  • Cook,
  • Sonova,
  • William Demant Holding A/S,
  • Nurotron Biotechnology Co. Ltd.,
  • Agilent Technologies,
  • Bio-Rad Laboratories, Inc.,
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Regional Analysis
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Evans Syndrome Market Growth And Restrain Factors Analysis By 2023

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome Market Information: by diagnosis (blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry), treatment (Splenectomy, Pharmacologic, Biologic therapy, Stem Cell), end user – Global forecast till 2023
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
It is estimated that the Evans Syndrome Treatment Market size is growing at a CAGR 10.2% during the forecast period of 2017-2023.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.

Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Detailed Table of Contents:
Table Of Contents
  1. Report Prologue
  2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
  1. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
 11 Appendix
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)